About
CDC's National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) works to reduce incidence of infection, morbidity and mortality, and health disparities in the U.S. and abroad. Read how NCHHSTP has worked to achieve these goals.

Guidance and recommendations
NCHHSTP publishes new or updated guidance and recommendations to prevent disease.
CDC Guidelines help prevent some STIs
CDC published clinical guidelines to prevent sexually transmitted diseases, including syphilis, gonorrhea, and chlamydia. Doxy PEP is the first new sexually transmitted infection (STI) prevention tool in decades and comes at an important time in the nation's fight against STIs. The initial clinical trials showed that doxy PEP reduces the risk of getting a bacterial STI by about two-thirds. In addition, recent "real-world" examples, show similar effects outside of formal trials, and one city has shown large scale benefits.
CDC asks for public input on new draft HIV recommendations
In December 2024, CDC posted for public comment draft Recommendations for HIV Screening in Clinical Settings.The draft HIV screening recommendations update the Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health Care Settings, published in 2006, and further support CDC's objectives to diagnose and link patients with undiagnosed HIV to clinical care; relink persons with previously diagnosed HIV to care; diagnose HIV infection earlier; and reduce HIV transmission in the United States.
These draft recommendations, expected to be finalized in early 2025, recommend at least one HIV test in a lifetime for all persons 15 years of age or older, updating the ages for HIV screening including eliminating an upper age limit. They also recommend improving implementation of HIV screening by encouraging providers to use clinical decision support tools (e.g., automated HIV test laboratory orders to implement HIV screening), recommending anyone who requests a test be tested, and emphasizing the use of a general consent process as used for other routine tests.
Point-of-care nucleic acid test for HCV
NCHHSTP worked with federal partners and industry to develop a new point-of-care nucleic acid test for HCV.
CDC's collaborative efforts with NIH, FDA, and a diagnostics company helped launch the first hepatitis C virus (HCV) point-of-care test that detects virus RNA and in doing so identifies people with active HCV infection. This new test allows the integration of testing and treatment in high-impact settings (such as mobile health units, opioid treatment programs, and large jails), which can provide and linking a person to care who tests positive for HCV RNA during the same health care visit, helping to ensure no loss to follow-up, and higher treatment completion rates to improve the health of the more than 2 million people with hepatitis C in the United States.
Annual surveillance reports
NCHHSTP's annual surveillance reports for HIV, Viral Hepatitis, Sexually Transmitted Infections, and Tuberculosis demonstrate meaningful reductions in some disease areas:
- Progress in HIV prevention continues, with an overall 12% reduction in HIV infections over the past four years.
- Gonorrhea cases dropped below pre-pandemic numbers and declined for a second year in a row, data show a decline in gonorrhea cases of 15% over past two years.
- Overall syphilis increased by only 1% after years of double-digit increases.
HIV self-tests
NCHHSTP's work with partners delivered 680,000 HIV self-tests to the homes of more than 300,000 during 2024 as part of the Together Take Me Home campaign.